Olomoucine
货号：
10010240-1mg 基本售价：
350.0 元 规格：
1 mg
产品信息
概述| 货号 | 10010240-1mg |
| 描述 | Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Olomoucine is a cdk inhibitor that acts by competing for the ATP binding site of the kinase. This purine derivative is an inhibitor for CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM), CDK/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAP kinase (IC50 = 25 µM).1 Olomoucine inhibits DNA synthesis in interleukin-2 stimulated T lymphocytes, triggers G1 arrest, and is also used to synchronize cells in G1.2 This inhibitor can attenuate astroglial proliferation and glial scar formation, decrease lesion cavity and mitigate functional deficits after spinal cord injury (SCI) in rats.3 Administration of olomoucine (3 mg/kg/day) to rats after SCI significantly suppressed microglial proliferation and proinflammatory cytokine expression, reduced tissue edema formation, and attenuated the number of apoptotic neurons.3 |
性能| 供应商 | Cayman |
| 应用文献 |
1.Vesely, J.,Havlicek, J.,Strnad, M., et al. Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224, 771-786 (1994).
2.Abraham, R.T.,Acquarone, M.,Andersen, A., et al. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biology of the Cell 83(2), 105-120 (1995).
3.Tian, D.S.,Xie, M.J.,Yu, Z.Y., et al. Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. Brain Research 1135, 177-185 (2007).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 298.3 |
| 分子式 | C15H18N6O |
| CAS号 | 101622-51-9 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
